Do you want to read an article? Please log in or register.
Interim FDG-PET improves treatment failure prediction in primary central nervous system Lymphoma: a LOC network prospective multicentric study
Lymphoma
Related content
Lymphoma
Rapid Tumor DNA Analysis of Cerebrospinal Fluid Accelerates Treatment of Central Nervous System Lymphoma
Blood
Gupta M, Bradley J, Massaad E, Burns E, Georgantas NZ, Maron G, Batten J, Gallagher A, Thierauf J, Nayyar N, Gordon A, Jones S, Pisapia M, Sun Y, Jones PS, Barker FG 2nd, Curry W, Gupta R, Romero J, Wang N, Brastianos P, Martinez-Lage M, Tateishi K, Forst DA, Nahed BV, Batchelor TT, Ritterhouse LL, Iser F, Kessler T, Jordan JT, Dietrich J, Meyerson ML, Cahill DP, Lennerz JK, Carter B, Shankar GM
doi: 10.1182/blood.2024023832
Lymphoma
Clinical characteristics and survival outcomes of patients with primary central nervous system lymphoma treated with high-dose methotrexate-based polychemotherapy and consolidation therapies
Eur J Cancer
de Groot FA, Dekker TJA, Doorduijn JK, Böhringer S, Brink M, de Groen RAL, de Haan LM, Woei-A-Jin FJSH, Noordenbos T, Sijs-Szabo A, Oudshoorn MA, Lam KH, Diepstra A, Te Boome LCJ, Terpstra V, Bohmer LH, Nicolae A, Posthuma EFM, Koens L, Durian MF, Stavast J, van der Poel MWM, Hamid MA, Stevens WBC, van Rooij SLM, Oostvogels RS, Mühlebner A, Neelis KJ, van den Brand M, Tousseyn T, Dierickx D, de Weerdt O, Beeker A, Jansen PM, Kersten MJ, Zijlstra JM, Chamuleau MED, Veelken H, Bromberg JCE, Nijland M, Vermaat JSP
doi: 10.1016/j.ejca.2024.115068
Lymphoma
Outcomes and Relapse Patterns in Primary Central Nervous System Lymphoma: Longitudinal Analysis of 559 Patients Diagnosed From 1983-2020
Neuro Oncol
Tringale KR, Scordo M, Yahalom J, White C, Zhang Z, Vachha B, Cederquist G, Schaff L, DeAngelis L, Grommes C, Imber BS
doi: 10.1093/neuonc/noae115
Multiple Myeloma (MM)
Central nervous system multiple myeloma: A real-world multi-institutional study of the Greek Myeloma Study Group
Am J Hematol
Katodritou E, Dalampira D, Delimpasi S, Ntanasis-Stathopoulos I, Karaolidou F, Gkioka AI, Labropoulou V, Spanoudakis E, Triantafyllou T, Kotsopoulou M, Michalis E, Vadikolia C, Papadopoulou T, Sevastoudi A, Michael M, Daiou A, Pentidou A, Kostopoulos I, Palaska V, Gavriatopoulou M, Kyrtsonis MC, Verrou E, Kastritis E, Dimopoulos MA, Terpos E
doi: 10.1002/ajh.27425
Lymphoma
CAR T-cell therapy induces a high rate of prolonged remission in relapsed primary CNS lymphoma: Real-life results of the LOC network
Am J Hematol
Choquet S, Soussain C, Azar N, Morel V, Metz C, Ursu R, Waultier-Rascalou A, di Blasi R, Houot R, Souchet L, Roos-Weil D, Uzunov M, Quoc SN, Jacque N, Boussen I, Gauthier N, Ouzegdouh M, Blonski M, Campidelli A, Ahle G, Guffroy B, Willems L, Corvilain E, Barrie M, Alcantara M, le Garff-Tavernier M, Psimaras D, Weiss N, Baron M, Bravetti C, Hoang-Xuan K, Davi F, Shor N, Alentorn A, Houillier C
doi: 10.1002/ajh.27316
Gynecologic Cancer
Risk-prediction models in postmenopausal patients with symptoms of suspected ovarian cancer in the UK (ROCkeTS): a multicentre, prospective diagnostic accuracy study
Lancet Oncol
Sundar S, Agarwal R, Davenport C, Scandrett K, Johnson S, Sengupta P, Selvi-Vikram R, Kwong FL, Mallett S, Rick C, Kehoe S, Timmerman D, Bourne T, Van Calster B, Stobart H, Neal RD, Menon U, Gentry-Maharaj A, Sturdy L, Ottridge R, Deeks J, ROCkeTS collaborators
doi: 10.1016/S1470-2045(24)00406-6
Lymphoma
Primary gastric diffuse large B-cell lymphoma: A multicentre retrospective study
Br J Haematol
Lewis CS, Joy G, Jensen P, Barraclough A, Franco N, Talaulikar D, Hawkes EA, El-Galaly TC, Villa D, Dickinson M, Seymour JF, Cheah CY
doi: 10.1111/bjh.19470
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study
★ 3
Recommended by
Dr Wolf-Dieter Janthur, Faculty Member
Ann Oncol
Lu S, Ahn MJ, Reungwetwattana T, Özgüroğlu M, Kato T, Yang JC, Huang M, Fujiki F, Inoue T, Quang LV, Sriuranpong V, Vicente D, Fuentes C, Chaudhry AA, Poole L, Armenteros Monterroso E, Rukazenkov Y, van der Gronde T, Ramalingam SS
doi: 10.1016/j.annonc.2024.08.2243
Breast Cancer
Efficacy outcomes of CDK4/6 inhibitors in combination with endocrine therapy treatment in hormone receptor-positive/HER2-negative advanced breast cancer according to PAM50 intrinsic subtype: Primary results of SOLTI-1801 CDK-PREDICT study
Eur J Cancer
Tolosa P, Pascual T, Martínez-Saez O, Hernando C, Servitja S, Fernández Abad M, Brasó-Maristany F, Sanfeliu E, Benitez Fuentes JD, Lema L, Ruano Y, García-Fructuoso I, Parrilla L, Rodríguez A, Roncero AM, Cobos MÁ, Sánchez-Bayona R, Alva M, Madariaga A, Villacampa G, Canes J, Salvador F, Sánchez-Belmonte A, Malumbres M, Prat A, Ciruelos E
doi: 10.1016/j.ejca.2024.115219